MedTrace Logo

Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury

NCT01621113 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2017-12-02

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy, safety, and tolerability of treatment with dalfampridine in combination with locomotor training in persons with chronic, motor incomplete SCI.

Conditions

  • Spinal Cord Injury

Interventions

DRUG

Dalfampridine

Dalfampridine 10 mg tablet, twice-daily, for 10 weeks

DRUG

Placebo

Placebo tablet, twice daily, for 10 weeks.

Sponsors & Collaborators

  • National Institute on Disability, Independent Living, and Rehabilitation Research

    collaborator FED

  • Acorda Therapeutics

    collaborator INDUSTRY

  • Kessler Foundation

    lead OTHER

Principal Investigators

  • Steven C. Kirshblum, M.D. · Kessler Institute for Rehabilitation

  • Gail F. Forrest, Ph.D. · Kessler Foundation

  • Trevor A. Dyson-Hudson, M.D. · Kessler Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2017-10-09
Completion
2017-10-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01621113 on ClinicalTrials.gov